

2023 CMSA Abstract

The Crazy Specialty of Pain Management:  
Advances and Controversies

October 12, 2023

Linda Vanni, MSN, PMGT-BC, ACNS-BC, NP, AP-PMN

Pain Management, Nurse Practitioner

Professional Pain Education & Consulting, LLC

# Michigan Educational Requirements for License Renewal

- \*Each medical doctor is required to complete 150 hours of continuing education in courses or programs approved by the board of which a minimum 75 hours of the required 150 hours must be earned in courses or programs designated as Category 1 programs. A minimum of 1 hour of continuing education must be earned in the area of medical ethics. Effective December 6, 2017 a minimum of 3 hours of continuing education must be earned in the area of pain and symptom management.
- \*Under Michigan law, all RNs and LPNs are required to complete 25 continuing education contact hours, with two hours of pain and symptom management, during the two years preceding application for license renewal. A one-time Human Trafficking CE is also required.
- \*R 338.7004 Implicit bias training standards Rule 4. 1) Beginning June 1, 2022 and for every renewal cycle thereafter, shall have completed a minimum of 1 hour of Implicit bias training for each year of the applicant's license or registration cycle. RNs two hours required.

# Objectives


After attending this session, professionals will be able to:

**Knowledge:** Demonstrate knowledge of evidenced-based pain management.

Describe the meaning of multimodal pain management.

Identify one future trend in pain management.

# The State of Pain



# Pain - by the numbers



## CHRONIC PAIN FACTS

### WHAT IS CHRONIC PAIN?

Chronic pain can be defined as pain that persists most days or every day for six months or more. For some individuals, pain can last a lifetime.

Chronic pain can take many forms:

- ☉ MILD TO SEVERE
- 🕒 INTERMITTENT TO CONTINUOUS
- 🚫 ANNOYING TO DISABLING

### Prevalence



**50 MILLION**

American adults, or 20 percent of the population, live with chronic pain.

**20 MILLION**

or 7% of American adults live with high-impact pain, or pain that frequently limits life or work activities.

Pain is the **NUMBER ONE** reason Americans access the health care system.



### Impact and cost



Chronic pain is **THE LEADING CAUSE** of long-term disability in the United States.



The nation spends up to **\$635 BILLION EACH YEAR** on chronic pain in terms of medical treatments, disability payments, and lost productivity.



Chronic pain has biopsychosocial implications. It is associated with **REDUCED QUALITY OF LIFE**, including increased risk of anxiety and depression.



**CHRONIC PAIN PATIENTS ARE OFTEN OVERLOOKED AND UNDERTREATED.**



Veterinary students **SPEND 5X** as many education hours focused on pain management as medical students.



For every **10,000 PEOPLE** with severe pain, there is only **ONE BOARD-CERTIFIED** pain specialist.



The National Institutes of Health dedicates approximately **2 PERCENT** of its funding to pain research.



At least **10 PERCENT** of all suicide cases in America involve someone with chronic pain.



Patients receive an average of **ONLY 30% PAIN REDUCTION** from their various treatments.



Studies have shown that **MINORITY GROUPS** and other marginalized populations are at risk of receiving suboptimal pain management.

76.9 billion is spent on the diagnosis and management of low back pain & an additional \$10-\$20 billion is attributed to economic losses in productivity each year.

Institute of Health Metrics & Evaluation, 2020



# Tolerance, Physical Dependence & Addiction

## • Tolerance

- Effects diminish over time. Tolerance is not an inevitable consequence of chronic opioid therapy

## • Physical dependence

- A predictable physiological response that occurs with continuous use
- Manifest by symptoms of withdrawal if use is abruptly discontinued or an antagonist is given
- Taper the dose to prevent withdrawal

## • Addiction

- A primary, chronic, neurobiologic disease: impaired control over drug use, compulsive use, craving and continued use despite harm
- Addiction is a complex condition, a brain disease that is manifested by compulsive substance use despite harmful consequence

### American Psychiatric Association, 2017 **Pseudo Addiction**


- “Addiction-like” behavior may signal inadequate pain control or intensification, progression of pain

A word cloud centered around the Opioid Crisis. The words are arranged in a roughly circular pattern, with the largest words being 'OPIOID CRISIS' and 'Addiction'. Other prominent words include 'Heroin', 'Withdrawal', 'Fatal', 'Abuse', 'Depression', 'Injections', 'Treatment', 'Policing', 'Families', 'Antidote', 'Overdose', 'Doctors', 'Political', 'Health', 'Addicts', 'Control', 'Usage', 'Communities', 'Deaths', 'Addiction', 'Fatal', 'Political', 'Usage', 'Laws', 'Epidemic', 'Adverse', 'Dependence', 'Detox', 'Drugs', 'Laws', 'Usage', 'Addicts', 'Control', 'Usage', 'Communities', 'Deaths', 'Addiction', 'Fatal', 'Political', 'Usage', 'Laws', 'Epidemic', 'Adverse', 'Dependence', 'Detox', 'Drugs', 'Laws', 'Usage', 'Addicts', 'Control', 'Usage', 'Communities', 'Deaths', 'Addiction', 'Fatal', 'Political', 'Usage'. The colors of the words include white, yellow, orange, red, green, blue, and purple.


Dependence Heroin Detox  
Adverse Withdrawal Drugs Fatal Laws  
Epidemic Depression Abuse Usage  
**OPIOID CRISIS**  
Communities Injections Usage  
Addiction Deaths Treatment Health  
Fatal Control Policing Addicts  
Antidote Families  
Drugs Doctors Political  
Overdose

# U.S. Opioid Dispensing Rates per 100 people, from 2006 to 2020

How have rates improved over time?



# Three Waves of Opioid Overdose Deaths




↑  
Wave 1: Rise in Prescription Opioid Overdose Deaths

↑  
Wave 2: Rise in Heroin Overdose Deaths Started in 2010

↑  
Wave 3: Rise in Synthetic Opioid Overdose Deaths Started in 2013

SOURCE: National Vital Statistics System Mortality File.





August 30, 2022  
Contact:  
For Immediate Release  
**Federal Law Enforcement  
Officials Warn of "Rainbow  
Fentanyl" Appearing in  
Oregon**



Drug Enforcement Administration




"Rainbow fentanyl—fentanyl pills and powder that come in a variety of bright colors, shapes, and sizes—is a deliberate effort by drug traffickers to drive addiction amongst kids and young adults. The men and women of the DEA are relentlessly working to stop the trafficking of rainbow fentanyl and defeat the Mexican drug cartels that are responsible for the vast majority of the fentanyl that is being trafficked in the United States."

DEA ADMINISTRATOR  
**ANNE MILGRAM**



# Total Study Population Change in Unadjusted Positivity Rate for Cocaine, Fentanyl, Heroin and Methamphetamine



# 1 in 7 High school students reported misusing Rx opioids at least once in their lifetime



- Schools can:
- ✔ Develop substance use prevention programs
  - ✔ Implement programs with individual, school, and family interventions

# COVID-19 and the opioid crisis: When a pandemic and an epidemic collide

STACY WEINER, SENIOR STAFF WRITER

JULY 27, 2020

- Researchers say it's too soon to have definitive data on the pandemic's effects, but early numbers are concerning. So far, alcohol sales have risen by more than 25%. A recent analysis of 500,000 urine drug tests by Millennium Health, a national laboratory service, also showed worrisome trends: an increase of 32% for nonprescribed fentanyl, 20% for methamphetamine, and 10% for cocaine from mid-March through May. And suspected drug overdoses climbed 18% in the same period, according to a national tracking system run out of the University of Baltimore.

# Advances

# Reversal Agents

- **Naloxone (pure opioid antagonist)**

Extremely short half life, 1.07-1.53h, normally longer than opioid being reversed. In the inpatient hospital setting (excludes ER), intravenous route, an ampule of naloxone (0.4mg/ml is diluted with 9 mls of saline for a final concentration of 0.04mg/ml). Initial dose of 2-3 mls administered and then titrated for effect to reverse opioid sedation.

Caution: Because of short life of naloxone, opioid half life is longer and additional doses of naloxone maybe required. Patient must be continually monitored.

**Now available over the counter-without a script- \$44.99**

- **Flumazenil (benzodiazepine antagonist)**

Reversal agent for benzodiazepines, binds to benzodiazepine receptors, enhances GABA effects. Intravenous route, 0.2-0.5 mg q min 1 mg., max 5 mg total.





SUSAN HOLMES-WALKER PHD, RN  
QUALITY RISK SPECIALIST II  
HENRY FORD HEALTH SYSTEM  
DAN MARKOS MSN, RN, AGCNS-BC, PMGT-BC  
CLINICAL NURSE SPECIALIST  
ST. JOSEPH MERCY ANN ARBOR

## Implicit Bias in Pain Management: What you Need to Know

# Implicit Bias Definition


"attitudes or stereotypes that affect our understanding, decision making, and behavior, without our even realizing it"

"Implicit bias in the courtroom", UCLA Law Review(2012) by Jerry Kang, et al.





# Disparities in Pain Care




Meints SM, et al. *Pain Manage.* 2019

# Long Hauler's Covid Symptoms


# Post acute sequelae of COVID-19 at 2 years

- Cohort of 138,818 individuals with SARS-CoV-2 infection
- 5,985,227 noninfected control group
- US Department of Veterans Affairs
- Followed for 2 years to estimate the risks of death & 80 prespecified post acute sequelae of COVID-19 (PASC)
- According to care setting during the acute phase of infection
- Among the hospitalized group
  - 50 sequelae (of 77) representing every organ statistically significantly elevated at 2 years
  - Suggesting difficult, protracted road to recovery
- Among the non-hospitalized group
  - Risks of 24 sequelae (of 77) remained elevated
  - Including several gastrointestinal, musculoskeletal and neurologic sequelae
  - Suggesting a longer-lasting risk horizon for these organ systems


Nature Medicine [Bowe, et al., 2023](#)



# Risk of post acute sequelae of COVID-19 up to 2 years after infection by care setting of the acute phase of the disease



# Michigan Automated Prescription system (MAPS)



# Assessment

- **The Problem with Pain-**


- **No pain-o-meter, no truth-o-meter!**
- **Cultural differences**
- **Diversity in non-verbal reactions to pain, e.g. stoic, red cell disorder patients**
- **If a patient has a specific surgery, should all patients receive the same pain medication (ortho power plans)**
- **We are influenced by our past experiences with patients**
- **Our biases, i.e. patient has SUD**
- **Purely subjective, typically measured with self-report scale 0-10**
  
- **Can self report be dangerous?**

# Definition of Pain

“Pain is whatever the experiencing person says it is, existing whenever he or she says it does.”

- Margo McCaffery, R.N., M.S., FAAN

# Multifactorial Nature of Pain



(Adapted from Portenoy, 1988)

# All about Function

- Patient examinations in physical therapy include, but are not limited to, testing of muscle **function**, **strength**, joint **flexibility**, range of motion, **balance** and **coordination**, posture, respiration, skin integrity, **motor function**, quality of life, and **activities** of daily living.



- Occupational therapy practitioners enable people of all ages to live life to its fullest by helping them promote health, and prevent—or live better with—injury, illness, or disability.



- To all the healthcare professionals practicing in the Rehab specialty including nurses, case managers, physical therapists, occupational therapists, and social workers. You have my deepest respect and admiration!

# Different Types of Pain

- **Somatic** – localized pain in skin, muscle, bone described as aching, stabbing, throbbing
  - Therapies for somatic pain include NSAIDs (prostaglandin inhibitors), acetaminophen (works centrally), muscle relaxants, ice, and heat
- **Visceral** – non-localized pain in organs or viscera described as gnawing, cramping, aching or sharp
  - Therapies for visceral pain include opioids (occupies opioid receptors), and interventional therapies
- **Neuropathic** – pain caused by nerve damage described as sharp, numbness, burning or shooting
  - Therapies for neuropathic pain include antidepressants (inhibits norepinephrine and serotonin re-uptake), anticonvulsants (blocks voltage-dependent calcium channels), local anesthetics, and interventional therapies  
**caution: anticonvulsants can cause dizziness, potential for falls. Start low and go slow!**
  - Opioids are not the medication of choice for neuropathic pain
- **These types of pain can occur individually or in combination**

# Acute Versus Chronic Pain

## Acute Pain

*Life sustaining symptom*

**Adaptive** by eliciting motivation to minimize harm and allow healing

## Chronic Pain

Pain persisting beyond expected healing  
*Can be a disease in and of itself*

**Maladaptive** disorder influenced by genetic and epigenetic factors

- **Nociceptive**: tissue or potential tissue damage including **somatic** (e.g., bones, joints, muscle) and **visceral** (e.g., mucosal injury, distention, ischemia)
- **Neuropathic**: disease or injury affecting the nervous system including **central** (e.g., trauma, stroke, neurodegenerative) and **peripheral** (e.g., compression, trauma, ischemia)
- **Nociplastic**: amplified processing of, or decreased inhibition of pain stimuli at **multiple levels in the nervous system** including diffuse sensitization (fibromyalgia), function visceral pain (IBS), regional somatic sensitization (complex regional pain syndrome)

# Neural Pathways of Pain





FIGURE 26.1 Neural pathways of pain. (Bullock, B.L. [2000]. *Focus on pathophysiology*. Philadelphia: Lippincott Williams & Wilkins.)



# Multi-modal Therapy: Clinical Advantages

## Peripheral

- Local anesthetics
- Opioids
- Anti-inflammatory agents
- Capsaicin

## Central


- Anticonvulsants
- Opioids
- $\alpha_2$ -agonist (clonidine)
- Acetaminophen

## Descending

- SNRIs, TCAs
- Endogenous systems

## Ascending

- Local anesthetics
- Anticonvulsants
- Opioids
- NMDA antagonists (ketamine)
- $\alpha_2$ -agonist (clonidine)



- Multimodal therapy provides a way to achieve balanced, safer pain therapy<sup>1</sup>
  - Improved quality of analgesia<sup>2,3</sup>
  - Fewer side effects<sup>2,3</sup>
  - Better functional status<sup>4</sup>

1. Gottschalk A, Smith DS. *Am Fam Physician*. 2001;63:1979-1984, 1985-1986.  
2. Tiippana EM, et al. *Anesth Analg*. 2007;104:1545-1556.  
3. Basse L, et al. *Brit J Surg*. 2002;89:446-453.

# Definition of Multi-Modal Pain Management

- A rational approach to pharmacologic therapy is to consider a drug's mechanism of action and the source or type of pain. Multimodal analgesia refers to the use of more than one agent from different pharmacologic analgesic classes that target different mechanisms of CNS or PNS pain.

ANA, 2011


- A multimodal approach to pain management (using two or more different methods or medications to manage pain) rather than using opioids alone.

ASA, 2018


# Goals of multimodal analgesia:

- **Improve analgesia quality**
- **Achieve more balanced analgesia**
- **Reduce adverse events** Galloway, 2011
- **Opioid-sparing**
- **Differences between multimodal, integrative, alternative pain management**

# Multimodal Pain Management Plan



# Assess for Opioid Misuse Risk Prior to Prescribing



Moore TM, et al. *Pain Med.* 2009  
\*Klimas J et al. *JAMA Network Open.* 2019

# Changing Winds

- Are we “opioided out”??
- Is there too much “baggage” with post-operative opioid use?
- What evidence-based pharmaceutical options do we have?
- Are there different mechanisms that can be used?
- Will nature point the way?
- Searching, searching, searching---always searching for the magic bullet!

Meta-Analysis

> [Lancet](#). 2022 Jun 18;399(10343):2280-2293.

doi: [10.1016/S0140-6736\(22\)00582-7](#).

# Opioid versus opioid-free analgesia after surgical discharge: a systematic review and meta-analysis of randomised trials

Julio F Fiore Jr <sup>1</sup>, Charbel El-Kefraoui <sup>2</sup>, Marc-Aurele Chay <sup>3</sup>, Philip Nguyen-Powanda <sup>2</sup>, Uyen Do <sup>2</sup>, Ghadeer Olleik <sup>2</sup>, Fateme Rajabiyazdi <sup>4</sup>, Araz Kouyoumdjian <sup>5</sup>, Alexa Derksen <sup>6</sup>, Tara Landry <sup>7</sup>, Alexandre Amar-Zifkin <sup>8</sup>, Amy Bergeron <sup>8</sup>, Agnihotram V Ramanakumar <sup>9</sup>, Marc Martel <sup>10</sup>, Lawrence Lee <sup>11</sup>, Gabriele Baldini <sup>12</sup>, Liane S Feldman <sup>11</sup>

Affiliations [+](#) expand

PMID: [35717988](#) DOI: [10.1016/S0140-6736\(22\)00582-7](#)

# Risk Factors for Developing Chronic Postsurgical Pain

## Alterations in:

- Expression of neurotransmitters, receptors, and ion channels
- Structure, connectivity, and survival of neurons

### Patient-related

- Younger
- Female
- History of
  - Anxiety
  - Depression
  - Catastrophizing
  - Pre-existing pain syndrome
  - Preoperative opioid use

**PERSISTENT  
PAIN**

### Intraoperative variables

- Surgical procedure and technique
- Nerve ligation/injury
- Ischemia
- Anesthetic modality


### **Postoperative pain**

- Uncontrolled high intensity pain
- Longer duration of postop pain


# Local Anesthetics

Blocks conduction of nerve impulses by decreasing or preventing an increase in the permeability of excitable membranes to  $\text{Na}^+$ .

(Catterall & Mackie, 1996)




# Ketamine for Acute Pain



- Developed in the 1960s as a dissociative anesthetic
- Subanesthetic doses studied for treatment of perioperative pain, neuropathic and nociplastic pain, depression and substance use disorders
- Analgesic without respiratory depression
- Increased use (IV, IM, intranasal [off-label]) as analgesic in ED and perioperative settings
- Decreases opioid requirements (“opioid-sparing”)
- Low oral bioavailability and very limited evidence for use in chronic pain
- Dose-dependent adverse effects including hallucinations, agitation, anxiety, dysphoria, euphoria
- Misuse potential due to psychoactive effects

# Acetaminophen

- Analgesic, antipyretic
- Well tolerated
- Used for both acute and chronic pain (Pros)
- Used to treat osteoarthritis
- Maximum dose 4000 mg/day, except w/ ETOH
- Inhibits prostaglandin synthetase in the CNS, weak peripheral anti-inflammatory activity, centrally acting, Reinforces the descending inhibitory serotonergic pain pathways (proposed)
- Risk of hepatotoxicity with higher doses, multiple combo products (Cons)
- Renal failure dosing based on creatinine clearance
- Moderately dialyzable
- Antidote – acetylcysteine (Mucomyst, Acetadote)



FSA HSA

**FIGHTS PAIN 2 WAYS:**

Acetaminophen **BLOCKS PAIN SIGNALS**

Ibuprofen **TARGETS PAIN AT THE SOURCE**

Acetaminophen **FOR ADULTS**  
Pain Reliever-Fever Reducer

**DISSOLVE PACKS**

NO WATER NEEDED  
DISSOLVES IN SECONDS

32 packets\*  
500 mg each packet


Berry Flavor  
Packets of Powder



# acetaminophen NSAIDs steroids



- 60 Patches
  - No Prescription Needed
  - 3 Effective Pain Fighters
- Camphor 3.1%  
Topical analgesic
- Methyl salicylate 10.0%  
Topical analgesic
- Menthol 6.0%  
Topical analgesic



# Buprenorphine



- Partial opioid agonist with formulations approved for treatment of pain or opioid use disorder (OUD)
- **Pain** (dosed in mcg)
  - Can precipitate opioid withdrawal if initiated while full opioid agonist highly bound
    - Taper prior opioid to  $\leq 30$  MME
    - Before starting buprenorphine

---

- **OUD** (dosed in mg)
  - Some formulations contain naloxone
  - Induction procedure to avoid precipitating opioid withdrawal
  - **OUD** dosed 1x/day
  - **OUD + Pain** dosed 3x/day

## Buccal 75-900 mcg q12-24

- Film shouldn't be cut, chewed or swallowed

## Transdermal 5-20 mcg/hr q 7 days

- Dosages (mcg/hr): 5, 7.5, 10, 15, 20 (max)
- Rotate sites wait min 3 wks before using same site

Sublingual tablets and film

Buccal tablets and film

SQ monthly injection

Maintenance  
~12-24 mg/d

# Beer's Criteria

- Created in 1991 to improve safety of med therapy in older adults
- Potentially inappropriate medication
  - All classes of medications
  - Evidence-based, graded tool
  - Assists health care providers in improving medication safety in the geriatric patient
- Covers side effects and potential adverse effects
  - TCAs: strong anticholinergics
  - NSAIDs: high rate of GIB in pts receiving for 3-6 months



# Controversies

# Marijuana in Michigan




## LEGALIZATION DAY

AS OF DEC. 6, MICHIGAN IS THE FIRST STATE IN THE MIDWEST TO LEGALIZE ADULT-USE RECREATIONAL MARIJUANA

- ✓ ADULTS 21 AND UP ARE PERMITTED TO POSSESS AND CONSUME MARIJUANA
- ✓ UP TO 2.5 OUNCES CAN BE POSSESSED AND TRANSPORTED AT ANY TIME
- ✓ UP TO 10 OUNCES CAN BE KEPT AT HOME; AMOUNTS HIGHER THAN 2.5 OUNCES MUST BE LOCKED AWAY
- ✓ UP TO 12 MARIJUANA PLANTS CAN BE GROWN IN THE HOME; MORE WITH A PROPER LICENSE

- ✗ DRIVING UNDER THE INFLUENCE OF MARIJUANA IS PROHIBITED
- ✗ CONSUMPTION OF MARIJUANA IN PUBLIC IS PROHIBITED
- ✗ MUNICIPALITIES MAY BAN RETAIL SALES OF MARIJUANA, BUT CANNOT BAN CONSUMPTION BY ADULTS 21 AND UP

*NOTE: MARIJUANA RETAIL SALES ARE NOT EXPECTED TO BEGIN UNTIL 2020*



# Cannabis and Pain

## Cannabis

- Contains >60 pharmacologically active cannabinoids including psychoactive THC and cannabidiol (CBD)
- Schedule I controlled substance (no currently accepted medical use)
  - Products with less than 0.3% THC are not considered a controlled substance



- Meta-analyses found moderate-quality evidence that cannabinoids can be effective for treatment of chronic pain, particularly neuropathic pain
  - **For 30% pain reduction** number needed to treat (NNT) was **24<sup>1</sup>** compared to **4-10 for TCAs, opioids, gabapentinoids, SNRIs<sup>2</sup>**
- “Very low certainty evidence from RCTs and observational studies are conflicting and leaves uncertainty whether the addition of medical cannabis affects the use of prescribed opioids among people living with chronic pain”<sup>3</sup>

1. Stockings E et al. *Pain* 2018
2. Noori A et al. *BMJ Open* 2021
3. Finnerup NB et al. *Pain* 2018

*What about CBD oil?*  
No THC right???



# “Unexpected Consequences” resulting from legalization of Recreational Marijuana

- Impaired driving
- New hire urine drug screen failure
- Does marijuana help trauma patients with their anxiety?
- Cyclic vomiting

# Cannabis Hyperemesis

---

## What is it?

- Cyclical pattern of hyperemesis every few weeks to months
- Months/years of cannabis use prior to onset and resolution with discontinuation
- Differential dx: Cyclical Vomiting Syndrome AKA Abdominal Migraine
- Distinguishing factor: symptoms relieved by hot bath or shower

## Pathophysiology

- Hypothesis: chronic overstimulation of the endocannabinoid receptors leading to alteration in the body's intrinsic control of nausea and vomiting
- May be related to its action on the TRPV-1 receptors in the periphery
- Change in composition of the plant over last 30 years could contribute: higher THC and lower CBD



# Cannabis Hyperemesis

Approximate  
time to diagnosis  
1-2 years

## Diagnostic Criteria: Rome IV Criteria

1. Criteria fulfilled for at minimum three months, with symptomatic onset occurring at least six months before diagnosis
2. Stereotypical episodic vomiting resembling cyclical vomiting syndrome in onset, duration, and frequency
3. Presentation after prolonged, excessive cannabis use
4. Relief of vomiting by a sustained cessation of cannabis use
5. May be associated with “pathologic” bathing behavior, e.g., prolonged hot baths and showers.

## How to treat it?

- Cessation of marijuana
- Antiemetics not effective ie: ondansetron, prochlorperazine
- Topical capsaicin 1% to epigastric area TID (mostly case studies but includes pediatrics)

# US National Cancer Institute Announces It Will Fund Cannabis-Cancer Research

News

🕒 Published: May 16, 2022



- Psilocybin may ease depression in some hard-to-treat patients
  - Modest effects waned over time
- 

### Colorado's ballot initiative

- Allow those 21 and older to use, grow, possess and share the psychedelic substances but not sell them for personal use
- Allow people who have been convicted of offenses involving the substances to have their criminal records sealed
- Unlike Colorado, the state allows counties to opt out of the program if their constituents vote to do so



Advances

# Genetic Polymorphism

UGT 1A1; involved in the glucuronidation of morphine, buprenorphine, and nalorphine.

UGT 1A3/1A4; glucuronidation of TCA.

UGT 2B7; glucuronidation of benzodiazepines.

- Genetic polymorphism: population distribution for inheriting liver enzyme activity controlled by a single gene locus.

CYP 2C19 approx. 18% Japanese and African Americans, 3-5% of whites, poor metabolizers with higher plasma conc. of drug substrates.

Ex. Diazepam, imipramine, and phenytoin.

CYP2D6 7-10% whites, 1-4% African Americans inherit autosomal recessive allele on chromosome 22 results in poor metabolism with higher plasma conc., prolonged half lives. Ex. Codeine-cannot convert codeine to morphine, paroxetine, venlafaxine, fluoxetine, desipramine, imipramine, nortriptyline and oxycodone.

**(Core, 2002), (Cleary & Hogan, 2007)**

## **\*\*\*FDA Drug Safety Communications**

**8/2012 Reviewing the safety of codeine administered post-tonsillectomy/adenoidectomy. 2/20/13 Black box warning issued. Deaths occurred in children ultra-rapid metabolizers with sleep apnea.**


# Equianalgesic Dosing

## \*Incomplete Cross Tolerance

Drug	Oral(mg)	IV (mg)	Duration (h)
morphine	30	10	3 - 4
hydromorphone	7.5	1.5	3 - 4
oxymorphone	10	1	> 4
methadone	2-5	2-5	6 – 8?
codeine	200	130	3 - 4
oxycodone	20-30	-	3 - 4
hydrocodone	30	-	3 - 4
meperidine	300	100	2 - 3

# Exciting New Possibilities


Genomic testing can help identify people with genetic variations so that doctors can make more informed prescribing decisions, reducing the risk of adverse events and increasing the likelihood of treatment success.



## Collaboration

The combined efforts of physicians, universities, the National Institute of Health (NIH) and the FDA are encouraging insurance acceptance and reimbursement by leading with Medicare.

Despite an upfront cost, the realized savings is well worth the investment.



## Ultrasound pain management device makes way for new FDA category

October 4, 2021

[Lois Levine](#)

The US Food and Drug Administration created a new category for ZetROZ's Acoustic Medicine device.



**Optimization and Validation of Ultrasound and Localized Drug Release Technologies**


Dr. George K. Lewis (PhD Neurobiology and Biomedical Engineering)  
President ZetROZ Systems





### International Approval

Focused ultrasound is approved to treat this condition outside the US. Patients can seek commercial treatment at participating international sites.

# Integrative Therapies



- *Ice/Heat*
- *Massage*
- *Distraction*
- *Music Therapy*
- *Positioning and Splinting*
- *Pet Therapy*
- *Hydo Therapy*
- *Aroma Therapy*
- *Acupuncture/Acupressure*
- *Yoga*
- *Transcutaneous Electrical Nerve Stimulation (TENS)*



# Tricks of the Trade

- Establish a relationship with the pain patient!
- Accept the patient's report of pain
- Do not assume patient is drug seeking, remember the possibility of a genetic variation
- Listen intently; you would be surprised what the patient may tell you
- Relay the need for accurate information regarding what the patient is taking for pain at home
- Discuss with patient how important it is to you that they communicate to you if their pain is being ineffectively managed
- Establish small goals; all about function

# Caring Behaviors in Pain Management

- Establishing a caring trusting relationship in pain management:

Opportunity to meet family members

One of the most vulnerable times

Desperately seeking help and hope!

The feeling of being totally alone, isolated!

Empathy

You have the ability to change someone's life **EVERYDAY!**